1. Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo
- Author
-
Chunxiao Chang, Zhifang Liu, Qingpeng Wang, Xuewen Hua, Dacheng Li, Jun Han, Zuojie Li, Linming Li, Yan Chen, and Zhengping Wang
- Subjects
Naproxen ,Biophysics ,Pharmaceutical Science ,chemistry.chemical_element ,Antineoplastic Agents ,Bioengineering ,Pharmacology ,Biomaterials ,Mice ,In vivo ,International Journal of Nanomedicine ,Cell Line, Tumor ,Drug Discovery ,medicine ,Animals ,Humans ,Bovine serum albumin ,Original Research ,Platinum ,Inflammation ,Cisplatin ,biology ,Chemistry ,metalloproteinases-9 ,Organic Chemistry ,bovine serum albumin nanoparticles ,inducible nitric oxide synthase ,Serum Albumin, Bovine ,General Medicine ,In vitro ,Oxaliplatin ,cyclooxygenase-2 ,Drug delivery ,biology.protein ,Nanoparticles ,synergistic antitumor efficacy ,medicine.drug - Abstract
Background Platinum(IV) complexes with inflammation inhibitory properties are much favored in improving antitumor activities. Nanodrug-delivery system as a preferable measure for antitumor therapy are widely explored in platinum(IV) drug delivery. Purpose The aim for this study was to develop novel bovine serum albumin (BSA) nanoparticles (NPs) based on naproxen platinum(IV) complexes to display a synergistic antitumor mechanism targeting cyclooxygenase-2 (COX-2), metalloproteinase-9 (MMP-9) and inducible nitric oxide synthase (iNOS). Methods Herein, we reported the preparation of two BSA NPs of naproxen platinum(IV) complexes, and their antitumor activities were investigated in vitro and in vivo. Results Both NPs possessed relatively uniform size and good stability for 30 days in aqueous solution. They exhibited prominent antitumor activities in vitro, and showed great potential in reversing drug resistance. Furthermore, these two NPs played superior tumor growth suppression in vivo in contrast to the free compounds, which were comparable to that of cisplatin and oxaliplatin, but induced lower toxic influences than platinum(II) drugs especially to spleen and liver. Moreover, the naproxen platinum(IV) NPs could decrease tumor inflammation targeting COX-2, MMP-9 and iNOs, and decreasing NO production, which would be in favor of enhancing the antitumor competence, and reducing toxicity. Conclusion Taken together, BSA NPs of naproxen platinum(IV) complexes demonstrated a powerful antitumor efficacy in vitro and in vivo. The platinum(IV) NPs with inflammation inhibitory competence targeting multiple enzymes reported in this work afford a new strategy for the development of antitumor therapy to overcome drawbacks of clinical platinum(II) drugs., Graphical Abstract
- Published
- 2021